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Abstract 
Osteoporosis is a chronic, progressive disease of multifactorial etiology characterized by low bone mass and 
microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility. The disease often 
does not become clinically apparent until a fracture occurs . It occurs in the elderly of both sexes but is most 
pronounced in postmenopausal women .The aim of this study was to assess the efficacy of sodium alendronate 
plus Thyme in treatment of postmenopausal women with osteoporosis and compare it's effect with Sodium 
alendronate alone . Forty postmenopausal women with osteoporosis were randomly divided into two groups( 
each group include twenty women) .The duration of treatment was 6 months . First group was given Sodium 
alendronate 70mg weekly and Thyme capsule 500mg twice daily, second group was given Sodium alendronate 
70mg once weekly .The following parameters were measured for two groups at baseline and at 6 months 
intervals bone mineral density(BMD) and t score except ESR and serum ionized calcium were measured at 
baseline and at 2 months interval . There were a significant increase in BMD and significant increase in t score in 
group treated with Sodium alendronate plus Thyme after 6 months as compared with baseline  and with group 
treated with Sodium alendronate . Also there were a significant reduction in mean serum ionized calcium and 
mean ESR in group treated with Sodium alendronate plus Thyme and group treated with Sodium alendronate 
alone after 2,4,6 months as compared with baseline(P<0.05) .                                                                                                               
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Introduction 
Osteoporosis is a progressive bone disease that is characterized by a reduce in bone mass and density which can 
cause an increased risk of fracture (1). In osteoporosis, the bone mineral density (BMD) is reduced,  and the 
quantity of  proteins in bone are changed . The disease increases morbidity and mortality, and it influences 
hundreds of millions of persons worldwide (2,3) .A recent meta-analysis showed reduce rates of fracture in older 
women with 80% or greater adherence to calcium supplementation (4) . Oral bisphosphonates suppress 
osteoclastic activity and are potent antiresorptive agents. Randomized clinical trials confirmed a reduction of   
hip and vertebral fractures with alendronate (
 
5,6) . Alendronate  also show effectiveness in men( 7,8) and in 
glucocorticoid-induced osteoporosis( 9,10).     Nitrogen-containing bisphosphonates suppress the mevalonate 
metabolic pathway, while bisphosphonates without   nitrogen are metabolized inside the cell  to give cytotoxic 
analogues of adenosine triphosphate . Bisphosphonates with very short plasma half-life , but the half-life of 
bisphosphonates deposited in bone with half-life  probably up to 10 years   and could be longer ( 11 ) . In large, 
randomized, controlled trials, alendronate decrease vertebral and non-vertebral fractures (5,12,13 ) . Rates of 
symptomatic vertebral fractures  were decrease by 28–36% over 3–4 years of treatment, while rates of 
asymptomatic and radiographically diagnosed vertebral deformities were decrease by 44–47% and of hip 
fracture by 51%. (14,15) . Bisphosphonates are  poorly absorbed from the GIT .Oral administration of 
alendronate  requires fasting before and directly after the drug is taken. It has been postulated that these drugs 
change both osteoclast function  and activation   (16,17) . Therefore, bisphosphonate compound inhibits the 
activity of osteoclast , enhances the mineral content of  bone in both hip and spine   when taken in a cyclic 
fashion (with or without a calcium supplement), and reduces the risk of fractures(18) . One review recorded that 
sage , thyme extract, rosemary, , and other plants, appear to inhibit osteoclast activity, increasing bone density in 
animals, but more study is needed in humans(19) . The essential oil of thyme (Thymus vulgaris), contains 20–
54% thymol (20) . Essential oil of Thyme also contains a range of additional compounds, like  linalool, myrcene, 
p-Cymene, and  borneol  (Chemical Composition of Thyme Essential Oil) . Thymol, an antiseptic, is the major 
active component in several commercially produced mouth washes  like   Listerine (21) . Before the discovery of 
modern antibiotics, thyme oil was used to medicate bandages(22) . Thymol has also been noted to be effective 
against different fungi that commonly infect toenails(23). Thymol can also be present as the active component in 
some natural, alcohol free hand sanitizers. In One study introduced  by Leeds Metropolitan University recorded 
that thyme may be helpful in treating acne (24, 25) . 
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Patients, Materials, and methods 
Patients 
This is a randomized prospective clinical trial study.  It was conducted in Merjan Teaching Hospital in DEXA 
unit which present in Rheumatology department. The study was conducted between March 2014 and March 
2015.The study was approved by ethical committee at Al- Nahrain University/Faculty of Medicine. 
 
Sample size 
The sample of the study include (40 postmenopausal women suffering from Osteoporosis) .They divide into two 
groups, each group include 20 patient . The duration of treatment is 6 months . 
 
Study Groups 
Group Ӏ:- received Sodium alendronate 70mg weekly plus Thyme capsule 500mg twice daily . 
Group  Ӏ Ӏ:-received Sodium alendronate 70mg once tablet weekly. 
All the following parameters were measured for all groups at baseline and at 2 months interval for  6 months 
duration except BMD ,t score was measured before treatment and 6 months of treatment, parameters include 
ESR, Serum ionized calcium. 
 
Data collection 
The method of collecting information depend on direct(personal) interview in a specific room    attached to unit 
DEXA measurement. The data were collected through the used of developed   questionnaire and the structured 
interview technique patients. Data  were collected  from the patients  in organized fashion and  individually with 
all the patients. The interview lasted for about (30) minutes, knowing that the data collection was only every 
Monday and Wednesday from every week, begin at 8: 00  am. and continue until 2:00 pm. 
 
Statistical analysis 
Statistical analyses were performed using SPSS 16.0 for windows.lnc. An expert statistical advice was consulted 
for tests used. Data of quantitative variables were expressed as mean ± SEM . Differences in each variable 
through treatment intervals in the same group were compared using paired-sample Student’s t-test. Analysis of 
Variance (ANOVA) followed by post-hoc tests using LSD method were used for the multiple comparisons 
among all groups. In all tests, P<0.05 was considered to be  statistically significant unless another levels were 
stated . 
 
Results   
Anthropometry  
Between the two groups included in this study, there were no significant difference in anthropometric data as 
shown in table (1).   
Table 1: Anthropometric data for all included patients in this study 
Anthropometric data Mean± SEM  
(Group Ӏ) 
Mean± SEM 
(Group Ӏ Ӏ) 
Age(year) 60.55±1.7 57.95±1.6 
Weight(kg) 81.65±3.11 79.85±3.81 
Height(cm) 154.4±1.42  155.15±1.61 
 
Effect of the two treatment regimen on BMD, t score, serum ionized calcium, ESR 
There were a significant reduction in mean serum ionized calcium, ESR in group treated with sodium 
alendronate plus thyme  after 2,4,6 months(P<0.05) as compared with baseline as shown in figure(1,2), also 
there were a significant increase in mean t score, BMD after 6 months(P<0.05) as compared with baseline as 
shown in figure(3,4) . There were a significant reduction in mean serum ionized calcium, ESR in group treated 
sodium alendronate  after 2,4,6 months(P<0.05) as compared with baseline as shown in figure(5,6), also there 
were a significant increase in mean t score, BMD  after 6 months(P<0.05) as compared with baseline as shown 
in figure(7,8) . In multiple comparison sodium alendronate plus thyme more efficacious than sodium alendronate 
alone in treatment of postmenopausal osteoporosis  as shown in table(2) .                                                                                                                    
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Table(2) percentage of patients remain osteoporosis, become osteopenia or normal after end of treatment                                                                                                                 
Osteoporosis 
(No. ,%) 
Osteopenia 
(No. ,%) 
Normal 
(No. ,%) 
 Group  
3, 15% 4, 20% 13, 65% 
Sodium alendronate plus 
Thyme   
4, 20% 6, 30% 10, 50%  Sodium alendronate 
 
Figure(1):-A comparative effect of Sodium alendronate plus Thyme on mean ionized calcium at different time 
interval 
(*) :- Mean there is a significant difference 
 
Figure(2):-A comparative effect of Sodium alendronate plus Thyme on mean   ESR at different time interval 
(*) :- Mean there is a significant difference 
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Figure(3):-A comparative effect of sodium alendronate plus Thyme on  mean t score at different time interval 
(*) :- Mean there is a significant difference 
 
Figure(4):-A comparative effect of Sodium alendronate plus Thyme on mean BMD at different time interval 
(*) :- Mean there is a significant difference 
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Figure(5):-A comparative effect of Sodium alendronate on mean serum ionized calcium at different time interval                                                 
(*) :- Mean there is a significant difference  
 
 Figure(6):-A comparative effect of Sodium alendronate on mean ESR at different time interval   
 (*) :- Mean there is a significant difference  
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Figure(7):-A comparative effect of Sodium alendronate on mean t Score at different time interval 
(*) :- Mean there is a significant difference 
 
Figure(8):-A comparative effect of Sodium alendronate on mean BMD at different time interval 
(*) :- Mean there is a significant difference 
 
Discussion 
According to a clinical practice guideline by the American College of Physicians, because of the significant 
disability, morbidity, mortality, and expenses associated with osteoporotic fractures treatment is aimed at 
fracture prevention(26). Preventive measures include modification of general lifestyle factors, such as increasing 
weight-bearing and muscle-strengthening exercise, which have been linked to fractures in epidemiologic studies, 
and ensuring optimum calcium and vitamin D intake as adjunct to active antifracture therapy(27) . Medical care 
includes the administration of adequate calcium, vitamin D, and anti-osteoporotic medication such as 
bisphosphonates,(28) parathyroid hormone (PTH), raloxifene, and estrogen(29) . In addition, potentially 
treatable underlying causes of osteoporosis such as hyperparathyroidism and hyperthyroidism should be ruled 
out or treated if detected. Surgical care includes vertebroplasty and kyphoplasty, which are minimally invasive 
spine procedures used for the management of painful osteoporotic vertebral compression fractures. However, 
there may be an increased risk of adjacent level vertebral fractures after these procedures(30,31) . 
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Effect of Sodium alendronate plus Thyme on different parameters of the present study 
The present study show a significant reduction in mean serum ionized calcium after 2,4,6 months treatment with 
sodium alendronate + thyme as compared with baseline mean serum ionized calcium  .These results were in a 
line  with the results of study by Cosman et al.,(32) , as they were given alendronate in combination with 
teriparatide hormone to postmenopausal osteoporosis for one year, they were reported that the elevated serum 
ionized calcium in osteoporosis was decrease because of alendronate stop bone matrix loss and teriparatide 
increase bone formation and help to mobilize calcium from the circulation to the bone, in our study given 
alendronate in combination with thyme do the same function because of alendronate stop bone loss and thyme is 
a good anabolic agent that increase bone formation and mobilize calcium from the circulation to the bone . 
The results of current study show a significant decreased in mean serum  ESR after 2,4,6 months 
treatment sodium alendronate + thyme as compared with baseline mean  ESR  . These results  were in a line with 
the results of study by  Nishizawa et al.,(33), in this study Fifty-four postmenopausal women with back pain 
were treated with alendronate (5 mg/day or 35 mg/week) and ECT (intramuscular, 20 units a week) (the 
ALN+ECT group), and 180 women without obvious back pain were treated with ALN alone (5 mg/day or 35 
mg/week) (the ALN group), The doses indicated in the parentheses above are the doses used in Japan for the 
treatment of postmenopausal women with osteoporosis and have been recognized as being safe and Effective(34), 
the duration of treatment 6 months ,biochemical markers were assessed such as serum ALP, ESR, they were 
found that serum ALP, ESR, were elevated before treatment and reduce after treatment, and the efficacy of 
combination treatment is more than single treatment, the interpretation for his variation were that in osteoporosis 
there were a loss of bone ALP and release of proinflammatory cytokines that initiate osteoclast activity and 
mediate bone resorption , thus this lead to increase serum ALP and ESR because ESR is a marker of 
inflammation, therefore treatment withis combination reduce osteoclast activity and had a role in increase 
osteoblast activity, so this lead to suppression of proinflammatory cytokines and mobilization of serum ALP to 
the bone , so decrease the elevated level of serum ALP, these findings were in accordance with findings of 
presentr study, because of alendronate inhibit osteoclast activity, so help to suppress proinflammatory cytokines, 
and ESR level was decrease. 
There were a significant increase in mean T score, BMD after 6 months treatment with sodium 
alendronate + thyme as compared with baseline mean T score, BMD.  These findings were had similarity with 
findings of study by Black et al.,(35), they were reported that the use of alendronate in combination with 
teriparatide for treatment of postmenopausal osteoporosis reduce bone removal and enhance bone mineral 
density , the interpretation for this were that alendronate was prevent loss of bone matrix by inhibiting osteoclast 
activity, and teriparatide enhance osteoblast activity , and thus increase bone formation, in present study, the 
combination of alendronate and thyme were had similar effect, alendronate decrease bone loss and thyme was 
anabolic agent that increase bone mineral density by increase osteoblast activity (36) . 
 
Effect of Sodium alendronate on different parameters of the present study 
In the present study there were a significant reduction in mean serum ionized calcium after 2,4,6 months 
treatment with sodium alendronate as compared with baseline mean serum ionized calcium . This finding was in 
accordance with that revealed by Royer et al.,(37) were demonstrated that alendronate inhibit osteoclastic bone 
resorption and are effective in the treatment of hypercalcemia due to conditions causing increased bone 
resorption and malignancy-related hypercalcemia . 
The present study show a significant reduction in mean ESR after 2,4,6 months treatment with sodium 
alendronate as compared with baseline mean ESR .The value of ESR in patient with osteoporosis, pregnancy, 
RA is high as compared with normal. It is a very common hematology test, and is a non-specific test of 
inflammation (38) . In present study the results of ESR were in accordance with results of Gregório et al., (39), 
they were stated that ESR should be assessed for all patients with osteoporosis as a marker of inflammation 
because of the inflammation has a major influence on bone metabolism and this lead to increase bone resorption 
and risk of fracture. All medication including bisphosphonates inhibit osteoclast activity lead to reduce 
inflammation ( 40) . 
The present study show a significant increase  in mean T-score ,BMD  after  6 months treatment with 
sodium alendronate as compared with baseline mean T score, BMD  . These results  were similar to results of 
study by  Luckey   et al.,(41), they were stated that weekly doses of alendronate 70 mg  is associated with a 4.7% 
increase in mean BMD values at the spine, 1.3% at the femoral neck and 2.9% at the total hip in postmenopausal 
women and results of  Yan et al.,(42), they were reported that increase in mean BMD (4.87% at the spine, 2.47% 
at the femoral neck, and 2.56% at the total hip) , this increments in BMD by alendronate due to that it's inhibit 
bone resorption and help to move calcium from the circulation to the bone, thus maintain calcium balance in 
bone  and T scores increased because of T scores compare a patient’s bone density to that of a healthy 30-year-
old of the same gender. The more negative the number, the less dense the bones(43) . 
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